Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23230962 | 0.88 | PDE4B (0.44) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL29745555 | 0.88 | PDE4B (0.44) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL29782298 | 0.88 | PDE4B (0.44) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216837 | 0.82 | MEN1 (0.37) | SMN1; SMN2HPGDMEN1KMT2ATSHR | |
| SCHEMBL23216642 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216448 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216947 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216825 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216140 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA | |
| SCHEMBL23216443 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2HPGDMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SMN1; SMN2 1712/4885HPGD 2590/4885MEN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.